Ulviprubart(Ulviprubart) - 药物靶点：KLRG1_在研适应症：包涵体肌炎，大颗粒淋巴细胞白血病_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

ABC 008、ABC-008、ABC008

靶点

KLRG1

作用机制

KLRG1抑制剂(杀伤细胞凝集素样受体亚家族G成员1抑制剂)

治疗领域

神经系统疾病皮肤和肌肉骨骼疾病其他疾病+ [3]

在研适应症

包涵体肌炎大颗粒淋巴细胞白血病

非在研适应症-

原研机构

Abcuro, Inc.初创企业

在研机构

Abcuro, Inc.初创企业

非在研机构-

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)、孤儿药 (美国)

登录后查看时间轴

序列信息

Sequence Code 682558281H

来源: *****

Sequence Code 682558534L

来源: *****

关联

4

项与 Ulviprubart 相关的临床试验

NCT06450886 / Active, not recruiting临床2/3期

An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and:
* Have completed the Part 2 (Multiple Ascending Dose [MAD]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR
* Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.

开始日期2024-10-21

申办/合作机构

Abcuro, Inc.初创企业

NCT05721573 / Active, not recruiting临床2/3期

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

开始日期2023-02-28

申办/合作机构

Abcuro, Inc.初创企业

[+1]

NCT05532722 / Active, not recruiting临床1/2期

A Study of ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

开始日期2022-09-28

申办/合作机构

Abcuro, Inc.初创企业

100 项与 Ulviprubart 相关的临床结果

登录后查看更多信息

100 项与 Ulviprubart 相关的转化医学

登录后查看更多信息

100 项与 Ulviprubart 相关的专利（医药）

登录后查看更多信息

1

项与 Ulviprubart 相关的文献（医药）

2019-06-28·Journal of microbiology and biotechnology4区 · 工程技术

Isolation and Characterization of Novel Chlorella Species with Cold Resistance and High Lipid Accumulation for Biodiesel Production

4区 · 工程技术

Article

作者: Kang, Nam Kyu ; Lee, Bongsoo ; Kim, Eun Kyung ; Park, Won-Kun ; Koh, Hyun Gi ; Chang, Yong Keun ; Suh, William

Chlorella spp. are green algae that are found across wide-ranging habitats from deserts to arctic regions, with various strains having adapted to survive under diverse environmental conditions. In this study, two novel Chlorella strains (ABC-002, ABC-008) were isolated from a freshwater lake in South Korea during the winter season and examined for possible use in the biofuel production process. The comparison of ABC-002 and ABC-008 strains with Chlorella vulgaris UTEX265 under two different temperatures (10°C, 25°C) revealed their cold-tolerant phenotypes as well as high biomass yields. The maximum quantum yields of UTEX25, ABC- 002, and ABC-008 at 10°C were 0.5594, 0.6747, and 0.7150, respectively, providing evidence of the relatively higher cold-resistance capabilities of these two strains. Furthermore, both the biomass yields and lipid content of the two novel strains were found to be higher than those of UTEX265; the overall lipid productivities of ABC-002 and ABC-008 were 1.7 ~ 2.8 fold and 1.6 ~ 4.2 fold higher compared to that of UTEX265, respectively. Thus, the high biomass and lipid productivity over a wide range of temperatures indicate that C. vulgaris ABC-002 and ABC-008 are promising candidates for applications in biofuel productions via outdoor biomass cultivation.

24

项与 Ulviprubart 相关的新闻（医药）

2024-11-11

·Business Wire

Abcuro Announces Participation in Upcoming Investor Conferences

NEWTON, Mass.--( BUSINESS WIRE )--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm E.T. Piper Sandler 36th Annual Healthcare Conference: Presentation on December 3, 2024, at 4:10 pm E.T. About Abcuro Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at abcuro.com .

免疫疗法

2024-08-29

·Business Wire

Abcuro Announces Participation in Upcoming Investor Conferences

NEWTON, Mass.--( BUSINESS WIRE )--Abcuro, Inc., a clinical stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Morgan Stanley 22 nd Annual Global Healthcare Conference: Presentation on September 5, 2024, at 2:35 pm E.T. Stifel Virtual Immunology and Inflammation Summit: Presentation on September 18, 2024, at 2:00 pm E.T. About Abcuro Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at abcuro.com .

免疫疗法

2024-07-31

·Business Wire

Abcuro Appoints Sarah Boyce to its Board of Directors

NEWTON, Mass.--( BUSINESS WIRE )--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Sarah Boyce to its Board of Directors. Ms. Boyce brings more than 25 years of global commercial leadership experience in the life sciences industry. “We are excited to welcome Sarah as a member of the Board and her experience will be instrumental as we focus on advancing ulviprubart in the ongoing Phase 3 MUSCLE trial for the treatment of inclusion body myositis,” said Mark Pruzanski, M.D., Chairman of the Board of Directors. “Sarah has extensive expertise in global product development, rare diseases and commercialization having helped bring over 20 products to market.” Ms. Boyce currently serves as the President and Chief Executive Officer of Avidity Biosciences, a publicly traded biotechnology company developing novel therapies for muscle wasting and other rare diseases. Prior to Avidity, she was President of Akcea Therapeutics and previously in her career held executive roles in business development and global operations for leading life sciences companies, including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and F. Hoffmann-La Roche AG. Ms. Boyce was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and one of the Fiercest Women in Life Sciences. She currently serves as a member of the Board of Directors at OmniAb and Contineum Therapeutics. Ms. Boyce holds a BSc (Hons) degree in microbiology from the University of Manchester, England. “I am thrilled to join Abcuro’s board at this critical point in the Company’s journey,” said Ms. Boyce. “I look forward to collaborating with the management team, providing guidance and sharing my expertise as the company progresses towards potential regulatory approval and readiness for potential commercialization.” About Abcuro Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at abcuro.com .

高管变更临床3期免疫疗法

100 项与 Ulviprubart 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
包涵体肌炎	临床3期	美国	Abcuro, Inc.初创企业	2023-02-28
包涵体肌炎	临床3期	澳大利亚	Abcuro, Inc.初创企业	2023-02-28
包涵体肌炎	临床3期	比利时	Abcuro, Inc.初创企业	2023-02-28
包涵体肌炎	临床3期	加拿大	Abcuro, Inc.初创企业	2023-02-28
包涵体肌炎	临床3期	法国	Abcuro, Inc.初创企业	2023-02-28
包涵体肌炎	临床3期	德国	Abcuro, Inc.初创企业	2023-02-28
包涵体肌炎	临床3期	英国	Abcuro, Inc.初创企业	2023-02-28
大颗粒淋巴细胞白血病	临床2期	美国	Abcuro, Inc.初创企业	2022-09-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04659031 (ABC008-IBM-101, EULAR2022)	临床1期	包涵体肌炎 large granular lymphocytes (LGLs)	6	ABC008 0.1 mg/kg	憲糧鹹積鏇鏇鏇選獵廠(壓範觸範廠鹽網遞網襯) = One unrelated serious AE of fall with muscle tear in a C1 participant with a prior history of falls occurred 醖遞糧憲憲鏇窪餘廠積 (繭壓壓築觸餘選製齋襯 )	-	2022-06-01
				ABC008 0.5 mg/kg